A Medical Device Daily

Tryton Medical (Newton, Massachusetts), reported marking "new milestones" in stent technology by a global demonstration of how the firm's Side-Branch Stent offers "unparalleled ease of use and the best option to safely and definitively treat bifurcation lesions."

Tryton transmitted a live satellite feed of a successful clinical case to an audience of interventional cardiologists at TCT Asia 2007 in Seoul, Korea, performed by Robert van Geuns, MD, PhD, a cardiologist at the Thoraxcenter of Erasmus Medical Center (Rotterdam, the Netherlands).

Patrick Serruys, MD, head of the department of interventional cardiology at the Thoraxcenter, moderated the event. "This technology has the capacity to redefine the treatment of bifurcation lesions and resolve a frequent dilemma of the interventional cardiologist," Serruys said.

The Side-Branch Stent also was featured at the American College of Cardiology's i2 Summit in New Orleans in March, where a live satellite feed of a clinical case performed by George Sianos, MD, senior interventionalist at the Thoraxcenter, was transmitted to demonstrate the ease of use and angiographic results that can be achieved by using the Tryton stent.

Another live case was performed in front of 1,000 interventional cardiologists at the Joint Interventional Meeting (JIM 2007) in Rome.

"Unlike other stents and techniques used to treat bifurcation lesions, Tryton's stent is easy to deliver as it uses standard equipment and techniques compatible with 5 and 6 French guiding catheters," said Sianos. "This device has greatly facilitated the treatment of these patients. The Tryton strategy allows the interventionist to secure the side branch and then treat the main vessel with his stent of choice."

"Tryton continues to demonstrate impressive results and growth as it becomes clear that our stent will eventually provide a new standard of care, thereby enabling any interventional cardiologists to treat the entire spectrum of bifurcation lesions they encounter every day," said H. Richard Davis, Tryton's chief technology officer.

"The benefits of our Side-Branch Stent have been witnessed by thousands of interventional cardiologists in Asia, Europe and America." He said. "While others pursue the elusive goal of treating bifurcation lesions, we are already definitively treating these lesions. Interventional cardiologists can quickly grasp how to use our stent to treat complex lesions. Tryton's dedicated save-the-side branch approach, allows for securing the side-branch first, after which the main vessel is stented in a predictable manner."

The company said that every year, more than half a million bifurcation coronary lesions are "sub-optimally treated, as no commercially available optimized solution exists for treating bifurcation lesions." As a result, it said cardiologists "are forced to ue a provisional strategy which avoids the deployment of a second stent — leaving the side branch vulnerable to thrombosis and restenosis."

Taxus Express2 is launched in Japan

In other coronary stent news, Boston Scientific (Natick, Massachusetts) said it has launched its Taxus Express2 paclitaxel-eluting stent system in Japan. The product was approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) on March 30; and reimbursement granted by the National Health Insurance System took effect May 1.

The company said the Taxus systems are the leading drug-eluting stents (DES) in markets outside of Japan. The number of coronary stents implanted annually in Japan is estimated at 200,000, making it the largest market in the world outside of the U.S.

Boston Sci said the Taxus stent systems "have been evaluated by the industry's most extensive randomized, controlled clinical trial program. The . . . systems have also been studied in more than 12,000 real-world patients enrolled in post-approval registries, in addition to 3 million Taxus stents implanted worldwide."

David McFaul, president and representative director of Boston Scientific Japan, said, "The Taxus stent offers Japanese physicians a broader choice of stent technologies and provides a deliverable treatment option with proven outcomes across a broad range of patients."

No Comments